Literature DB >> 9294611

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

C A Midgley1, D P Lane.   

Abstract

The tumour suppressor protein p53 is expressed at very low levels in normal cells but accumulates in response to DNA damaging agents such as u.v. irradiation. This increase is accompanied by transcriptional upregulation of the expression of a number of proteins including Mdm2 which can in turn inhibit p53 dependent transcriptional activation, creating a feedback loop resulting in down-regulation of p53 activity. Mutant p53 proteins are however frequently detected at constitutively high levels in many tumours and tumour cell lines, indeed this phenomenon has been used in several studies to diagnose p53 mutation in patient tumours. We show here that expression of mouse mutant p53 in tumour cell lines of this type results in high levels of both the endogenous p53 protein and the exogenously expressed mutant mouse protein, whereas the human tumour line MCF7 does not exhibit high levels of either endogenous human or exogenously expressed mouse mutant p53 unless stabilisation is induced by DNA damage. This suggests that the stability of mutant p53 is not intrinsic to mutant p53 protein structure but may vary in different cell backgrounds. We present evidence that p53 protein stability in tumour cell lines is determined by association with the Mdm2 tumour suppressor protein, and that p53 mutants which are unable to bind Mdm2 are stable in MCF7 cells. We propose that tumour lines which express high levels of transcriptionally inactive mutant p53 are unable to induce the expression of the Mdm2 protein which would normally provide a feedback mechanism down-regulating p53 protein levels in the absence of DNA damage signals. MCF7 cells however express a transcriptionally active p53 and retain the feedback regulation of p53 protein levels by Mdm2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294611     DOI: 10.1038/sj.onc.1201459

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  97 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

3.  Identification of a sequence element from p53 that signals for Mdm2-targeted degradation.

Authors:  J Gu; D Chen; J Rosenblum; R M Rubin; Z M Yuan
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 4.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

5.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 6.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

7.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

8.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.

Authors:  T Unger; T Juven-Gershon; E Moallem; M Berger; R Vogt Sionov; G Lozano; M Oren; Y Haupt
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

9.  Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53.

Authors:  C Blattner; A Sparks; D Lane
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

10.  p53: a molecular marker for the detection of cancer.

Authors:  Mark T Boyd; Nikolina Vlatkovic
Journal:  Expert Opin Med Diagn       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.